{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["57(2)"],"submitter":["Schmid C"],"pubmed_abstract":["We report on 318 patients with acute leukemia, receiving donor lymphocyte infusion (DLI) in complete hematologic remission (CHR) after allogeneic stem cell transplantation (alloSCT). DLI were applied preemptively (preDLI) for minimal residual disease (MRD, n = 23) or mixed chimerism (MC, n = 169), or as prophylaxis in high-risk patients with complete chimerism and molecular remission (proDLI, n = 126). Median interval from alloSCT to DLI1 was 176 days, median follow-up was 7.0 years. Five-year cumulative relapse incidence (CRI), non-relapse mortality (NRM), leukemia-free and overall survival (LFS/OS) of the entire cohort were 29.1%, 12.7%, 58.2%, and 64.3%. Cumulative incidences of acute graft-versus-host disease (aGvHD) grade II-IV°/chronic GvHD were 11.9%/31%. Nineteen patients (6%) died"],"journal":["Bone marrow transplantation"],"pagination":["215-223"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8821014"],"repository":["biostudies-literature"],"pubmed_title":["Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia."],"pmcid":["PMC8821014"],"pubmed_authors":["Schmid C","Schaap N","Mohty M","Baron F","Bug G","Brecht A","Labopin M","Veelken H","Finke J","Esteve J","Collin M","Tischer J","Gorin NC","Ljungman P","Savani B","Ciceri F","Giebel S","Kulagin A","Stadler M","Blaise D","Nagler A","Bloor A"],"additional_accession":[]},"is_claimable":false,"name":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.","description":"We report on 318 patients with acute leukemia, receiving donor lymphocyte infusion (DLI) in complete hematologic remission (CHR) after allogeneic stem cell transplantation (alloSCT). DLI were applied preemptively (preDLI) for minimal residual disease (MRD, n = 23) or mixed chimerism (MC, n = 169), or as prophylaxis in high-risk patients with complete chimerism and molecular remission (proDLI, n = 126). Median interval from alloSCT to DLI1 was 176 days, median follow-up was 7.0 years. Five-year cumulative relapse incidence (CRI), non-relapse mortality (NRM), leukemia-free and overall survival (LFS/OS) of the entire cohort were 29.1%, 12.7%, 58.2%, and 64.3%. Cumulative incidences of acute graft-versus-host disease (aGvHD) grade II-IV°/chronic GvHD were 11.9%/31%. Nineteen patients (6%) died","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-25T22:29:26.42Z","creation":"2025-02-19T03:47:18.423Z"},"accession":"S-EPMC8821014","cross_references":{"pubmed":["34750562"],"doi":["10.1038/s41409-021-01515-3"]}}